Bulky disease is the most important prognostic factor in XXXX stage IIB.

@entity1 @entity978
The aim of this study was to evaluate treatment results for @entity978 ( @entity978 ) @entity1 younger than 60 yr in stage IIB, treated according to the Swedish National Care Programme. The intention was also to identify specific subgroups depending on the number of negative prognostic factors the @entity1 have, in order to optimise and differentiate future treatment. In total, 99 @entity1 with @entity978 stage IIB, diagnosed between 1985 and 1994, have been analysed. There were 47 @entity1 and 52 @entity1 and the median age was 33 yr (range 17-59). Eighty-six @entity1 presented with supradiaphragmatic disease and 13 with infradiaphragmatic. The @entity978 specific and overall 10-yr survival was 73 and 65%, respectively. The @entity978 -specific survival for @entity1 in pathological stage IIB tended to be better, although not statistically significant than for clinical stage IIB, despite less chemotherapy (P = 0.1). The @entity1 in stage IIB who were selected for laparotomy were, however, younger and with fewer negative prognostic factors. The only significant negative prognostic factor was bulky disease (P = 0.001). The following factors also tended to have a negative influence on the prognosis although not statistically significant: the International Prognostic Score, the number of involved lymph node stations, extranodal involvement and leucocyte count > 15 x 10(9)/L. In conclusion, we suggest that bulky disease should be taken into account when treating @entity1 with stage IIB @entity978 .
